AI Verdict
RMR has stronger fundamentals based on our AI analysis.
RNA vs RMR Fundamental Comparison
| Metric | RNA | RMR |
|---|---|---|
| Revenue | N/A | $180.4M |
| Net Income | N/A | $12.2M |
| Net Margin | N/A | 6.8% |
| ROE | N/A | 5.2% |
| ROA | N/A | 1.8% |
| Current Ratio | N/A | 1.82x |
| Debt/Equity | N/A | 0.19x |
| EPS | N/A | $0.71 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RNA vs RMR: Frequently Asked Questions
Is RNA or RMR a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RMR has stronger fundamentals. RNA is rated SELL (20% confidence) while RMR is rated HOLD (62% confidence). This is not investment advice.
How does RNA compare to RMR fundamentally?
Atrium Therapeutics, Inc. has ROE of N/A vs RMR GROUP INC.'s 5.2%. Net margins are N/A vs 6.8% respectively.
Which stock pays higher dividends, RNA or RMR?
RNA has a dividend yield of N/A or no dividend while RMR has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RNA or RMR for long term?
For long-term investing, consider that RNA has SELL rating with 20% confidence, while RMR has HOLD rating with 62% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RNA vs RMR?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RNA vs RMR, the AI consensus favors RMR based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.